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The COVID-19 pandemic has had significant implications not only for health but also for
lifestyles and for organizations both in the healthcare sector and in other spheres. Before
December 2019, other coronaviruses had been described that had presented endemically and
in some cases caused epidemics, but none spread to such an extent globally; the COVID19 pandemic is reminiscent of other historic epidemics such as the influenza epidemic of the
last century, whose sequelae, including neurological symptoms, were felt for decades (1). Of
the other coronaviruses (CoV) affecting humans, 2 are classified as αCoV (HCoV-229E and
HKU-NL63) and 4 as βCoV (HCoV-OC43, HCoV-HKU1, SARS-CoV, and MERS-CoV). SARSCoV and MERS-CoV caused severe infections both in healthy individuals and in people with
immune deficiencies, and were associated with high mortality rates, whereas the others are
associated with seasonal outbreaks of flu-like symptoms with relatively limited capacity for
transmission. However, all of these viruses have either been associated with neurological symptoms
or been detected in biological samples taken from the central nervous system (CNS) (2, 3).
On 31 December 2019, the World Health Organization reported a novel CoV (SARS-CoV-2)
in patients with pneumonia in the city of Wuhan, in the Chinese province of Hubei, which
spread rapidly through the rest of the world. The novel virus is a βCoV and bears considerable
similarity to SARS-CoV. The main structural differences between SARS-CoV and SARS-CoV2 are observed in the fusion protein and in accessory proteins, particularly ORF3b and ORF8.
As is the case with SARS-CoV, subunit 1 of the novel coronavirus fusion protein also binds
to the ACE2 receptor, hence the name SARS-CoV-2 (4). It has been suggested since early in
the pandemic that the virus may have direct and indirect effects on the CNS (5), with many
researchers and authors beginning to analyze a pandemic with worldwide effects; an enormous
amount of information has been generated, largely due to the scientific community’s desire for
progress. However, much of this information is from case reports, anecdotal series, and many
speculative articles based more on opinion than experimentation (6). Despite the great efforts
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to generate evidence to enable advances in our understanding of
the virus and associated disease, much speculation remains today
with regard to the evidence. Such aspects as its epidemiology,
transmission factors, and the impact of mass vaccination are
conditioned by data from studies that present considerable bias
(7) and are not evidence-based.
Since the beginning of the pandemic, there has been debate
as to whether SARS-CoV-2 is able to enter the CNS and
cause neurological symptoms, trigger or promote pre-existing
neurological disease, or remain latent in the brain, making the
organ a viral reservoir (5). The study of the potential routes by
which the virus enters the CNS (i.e., the hematogenous route or
the neuronal route), facilitating this penetration, also constitute
an interesting area of research (8, 9) analyzing whether the virus
accesses the CNS by infecting endothelial or epithelial cells of
the blood-brain barrier; by dissemination from nearby areas; or
by axonal transport after infecting neurons in the peripheral
nervous system. Another subject of debate is the frequency
of neurological symptoms associated with the acute infection
(10, 11) and their association with the CNS (12), and associated
neurological disorders such as stroke (13, 14) and neuromuscular
involvement (15). Furthermore, there is an interesting debate as
to whether the virus can trigger neurological disease, for example
neurodegenerative disease, in the long term (it has been suggested
that the infection may increase the risk of Parkinson’s disease
or Alzheimer’s disease), and by which mechanisms (16, 17), and
whether it may facilitate age-related transcriptome or molecular
changes (18). Finally, there is controversy regarding the so-called
persistent COVID-19 or post–COVID-19 syndrome, referring to
symptoms persisting for 3 months after the acute infection, with
particular emphasis on cognitive symptoms (19). A recent Delphi
consensus study conducted by the World Health Organization
establishes 3 major criteria for diagnosing post–COVID-19
condition, 2 of which are based on the presence of neurological
symptoms: fatigue and cognitive alterations (20).
The special issue “COVID-19 in CNS and PNS: Basic
and Clinical Focus on the Mechanism of Infection and New
Tools for the Therapeutic Approach” includes valuable articles
addressing these debates, contributing evidence to expand our
understanding of the disease and its impact on the CNS.

reviewed 280 studies, selecting 33 for meta-analysis, and report
neurological alterations such as myalgia in 19.2% of patients,
headache in 10.9%, and stroke in 4.4%; they also review the
frequency and characteristics of neurological symptoms during
the pandemic. Fiani et al. present an extensive review addressing
the impact of neurological manifestations and the underlying
mechanisms. The article by Gori et al. specifically studies the
frequency and pathogenesis of anosmia, taking a very broad
approach, analyzing the possible pathogenic mechanisms and
addressing the current controversies; Mathew also contributes
an interesting article on anosmia. Hwang et al. analyzed the
presence of seizures during SARS-Cov-2 infection in 4 of their
own patients and review the literature on the subject, whereas
Waters et al. describe the incidence of electroencephalographic
seizures. Zito et al. analyzed Guillain-Barré syndrome in patients
with COVID-19 in a case report and meta-analysis of 29
articles. Jungbauer et al. analyze vocal cord palsy associated
with SARS-CoV-2 infection. The study by Varela Rodríguez
et al. addresses neuropsychiatric symptoms in patients with
COVID-19 and history of alcohol abuse. Román et al. present a
comprehensive clinical review of transverse myelitis associated
with COVID-19 and vaccination against the disease, a highly
informative contribution. Severa et al. discuss treatment with
interferon beta in the context of COVID-19. Together, these
articles offer a panoramic view of the neurological symptoms
associated with COVID-19.

CONTRIBUTIONS ON THE MECHANISM
OF CENTRAL NERVOUS SYSTEM
INVASION
This special issue includes several key articles. Huang et al.
review the association between biological and molecular factors
associated with the viral infection and their potential effects
on the CNS. They propose the murine hepatitis virus as a
model for studying the role of coronaviruses in the CNS;
Sanclemente-Alaman et al. also highlight this model in their
review of experimental models of SARS-CoV-2. Wang et al.
review the action mechanisms of viruses affecting the CNS
in an article on neurological symptoms of COVID-19 and
offering an overview of the clinical manifestation and infection
mechanisms. Reza-Zaldívar et al. analyze specific mechanisms
associated with SARS-CoV-2. Gomes de Assis et al. address the
underlying mechanisms of neurological symptoms associated
with COVID-19 after reviewing 484 articles according to a
pre-established methodology addressing different fields, such
as host factors, immune mechanisms, and virology. This
comprehensive study presents both experimental and clinical
data. Guadarrama-Ortiz et al. conducted an exhaustive review
of neurological manifestations, viral entry routes, and potential
immune and virological mechanisms, discussing a broad range
of potential neurological alterations affecting both the central
and the peripheral nervous systems. This interesting review
presents an overview of the relationship between SARS-CoV2 and neurological symptoms. The virus is very difficult to
detect or undetectable in the cerebrospinal fluid of patients

CONTRIBUTIONS ON NEUROLOGICAL
SYMPTOMS DURING THE ACUTE PHASE
Several articles have contributed new information on
neurological manifestations of COVID-19. For instance,
Yan et al. analyze neurological symptoms in a retrospective
series of 1,682 patients from Wuhan, with 30.3% presenting
neurological symptoms (12.8% with headache). Tsai et al.
reviewed 79 studies, selecting 63 for inclusion in a metaanalysis. These researchers report olfactory alterations in 35%
of patients, headache in 10.7%, and stroke in 8.1%. Kushwaha
et al. conducted a cross-sectional study analyzing data from 358
patients with neurological symptoms, 69 of whom had suspected
SARS-CoV-2 infection, and evaluate the impact of the infection
at a center primarily attending neurological patients. Pinzon et al.
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MOVING TOWARD A BETTER
UNDERSTANDING OF THE EFFECTS OF
SARS-COV-2 ON THE CNS AND THEIR
LONG-TERM IMPLICATIONS

with SARS-CoV-2 infection, even in those with encephalitis,
according to the transcriptome analysis of cerebrospinal fluid
samples by Placantonakis et al.; Pacheco-Herrero et al. studied
neuropathological aspects of the infection.

CONTRIBUTIONS ON HOST FACTORS
AND THE RISK OF NEUROLOGICAL
DISEASE

It remains to be determined whether the virus or its RNA can
remain within structures of the CNS or whether it may remain
latent or cause disease in the long term; therefore, there is a
clear need for necropsy studies (21, 22). It also seems important
to identify any areas of the CNS that may present greater
vulnerability to infection (though the hippocampus and basal
ganglia have been suggested), whether some CNS cells present
greater susceptibility to viral structures, and whether the virus or
its RNA may be transported by such cell substructures as vesicles
or exosomes. It is also unclear whether existing lesions, such as
demyelinating plaques in multiple sclerosis, may facilitate the
entry of the virus and serve as viral reservoirs. The impact of
different types of vaccine on viral invasion of the CNS is another
area where further study is needed. The effects of SARS-CoV-2 on
the brain constitute a new challenge for neuroscientific research
(23), in which we may only advance with the greatest possible
quantity of information, like that included in this special issue.

Bhaskar et al. comprehensively review the immune response
associated with SARS-CoV-2 infection, placing special emphasis
on the cytokine storm, as well as immunosenescence, and the
role of these mechanisms in complications. Severa et al. analyzed
the possible relationship between the use of interferon beta and
the risk of infection, as well as the drug’s role in the clinical
course of the disease, considering its potential therapeutic role
in COVID-19, as occurred in previous coronavirus epidemics.

CONTRIBUTIONS ON NEUROLOGICAL
SEQUELAE AFTER ACUTE SARS-COV-2
INFECTION AND PERSISTENT COVID
SYNDROME
D’Arcy et al. discuss the long-term consequences of the infection.
Fiani et al. analyzed persistent neurological symptoms after the
infection, calling attention to the need for guidelines addressing
sequelae of stroke, intracranial infections, and muscle damage, as
well as nutrition-related issues.
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